Episode Summary
Executive Summary: Dr. Mark Hyman and the host discuss how AI, lab testing, wearables, and personalized data are shifting healthcare from passive, fragmented disease management to proactive self-directed health. The conversation centers on Function Health’s mission, the value of broad biomarker screening, interpretation via AI plus clinician oversight, and broader concerns about obesity, metabolic dysfunction, mental health overprescribing, and emerging psychedelic therapies.
Main Topics: Function Health and democratized access to biology (Priority: 5/5): Hyman explains Function as a personal health platform that gives people ownership of their medical data, affordable lab access, and AI-assisted interpretation so they can understand and improve their health without relying solely on traditional doctors or insurance gatekeepers. Data-driven preventive medicine (Priority: 5/5): The discussion contrasts old-school episodic care with a new model built on longitudinal data, including labs, imaging, wearables, EMRs, and omics, to detect risk earlier and guide individualized action. Healthcare dysfunction and cost barriers (Priority: 5/5): Both speakers criticize U.S. healthcare for high costs, poor transparency, and weak preventive infrastructure, arguing that many people delay care or are forced into concierge medicine to get meaningful attention. Metabolic health, obesity, and insulin resistance (Priority: 5/5): Hyman argues that most Americans have undiagnosed metabolic dysfunction, with insulin testing underused and blood sugar often appearing normal until disease is advanced. He highlights diet, sugar, and processed foods as major drivers. Wearables, food experiments, and behavior change (Priority: 4/5): The host shares experiments with continuous glucose monitoring, sleep tracking, and activity changes, while Hyman supports wearables as useful tools for feedback, behavior change, and early warning signals. GLP-1 medications and strength preservation (Priority: 4/5): They discuss GLP-1s as helpful but not magic, emphasizing that they should be paired with nutrition, protein intake, and resistance training to avoid muscle loss and rebound weight gain. Mental health, nutrition, and psychedelics (Priority: 4/5): Hyman argues many psychiatric issues are rooted in biological factors like nutrient deficiency and insulin resistance, and he supports rigorous research into psychedelic therapies as a promising but not yet ready-for-prime-time frontier.
Key Arguments: Most doctors still rely on minimal data and intuition rather than broad technology-assisted decision-making, which limits preventive care and root-cause analysis. Function Health tries to bridge the gap between concierge medicine and ordinary healthcare by offering affordable, high-volume testing and AI-based interpretation. Insulin resistance is massively underdiagnosed; blood sugar alone is too late a marker to catch metabolic dysfunction early. Wearables and self-experimentation can reveal personalized responses to food, sleep, alcohol, and exercise that generic advice misses. GLP-1s can be valuable tools for obesity and metabolic disease, but they require medical oversight and should be combined with lifestyle changes to protect muscle mass. Many mental health symptoms may stem from modifiable biological issues such as low omega-3s, vitamin D, B vitamins, magnesium, and insulin resistance. Psychedelic therapies may become important in psychiatry, but should be studied rigorously and used carefully rather than casually or recreationally.
Data Points: Americans skipping doctor visits due to cost: 1 in 3 - Used to illustrate access barriers in U.S. healthcare. Americans with chronic illness: 6 out of 10 - Cited as evidence of widespread disease burden. Americans with metabolic dysfunction: 93% - Presented as an alarming population-level estimate. Americans overweight or obese: 75% - Used to show the scale of obesity-related dysfunction. Americans with high insulin levels: 65% - Function Health screening result; emphasized that insulin is rarely checked. Function biomarkers tested per year: 160+ biomarkers twice a year - Described as part of the membership offering. Function membership price: about $1 a day / $365 per year - Positioned as affordable compared with concierge medicine or retail testing. Retail price of comparable lab stack: about $15,000 - Hyman contrasted Function pricing with traditional personalized lab work. Whole-body MRI scan price: $1,199 - Mentioned as a relatively affordable imaging add-on. Multi-cancer early detection performance: ~75% detection rate across 15+ cancers - Described as the Gallery test offered through Function. Function biomarkers processed total: 100+ million biomarkers - Used to show scale of platform usage. Patients with nutritional deficiency on Function: almost 70% - Reported as lab low values, not necessarily optimal ranges. Patients with high APO-B: 54% - Highlighted as an important but underused cardiovascular marker. Severe adverse side effect rate for GLP-1s: about 4% - Hyman cited this as a caution for large-scale use. GLP-1 digestive side effects: about 75% - Referenced as common tolerability issue. Cereal vs ice cream glucose experiment: Cereal spiked glucose much more than ice cream - Illustrated how fat/protein blunt glucose response compared with processed carbs. Whole-food intervention in detention centers: violent crime down 97%, restraints down 75%, suicide down 100% - Cited to argue that food quality affects behavior and mental health.
Pivotal Quotes: "We have a staggering problem that is not being addressed by our system." — Dr. Mark Hyman: Opening argument about chronic disease and healthcare failure. "Function is really about giving people agency, democracy. Democratizing healthcare and allowing people access to their own biology." — Dr. Mark Hyman: Defines the philosophy behind Function Health. "It's gone from terrible to actually pretty good." — Dr. Mark Hyman: His assessment of LLM performance for health-related decision support.
Implications: Listeners are encouraged to treat health as measurable and self-directed, using labs, wearables, and AI to catch problems earlier. For healthcare, the conversation points toward a future of personalized, data-rich prevention with stronger scrutiny of drugs, psychiatry, and system-wide inefficiencies.
About This Week in Startups
Jason Calacanis covers startups, tech, markets, media, and all the hottest topics in business and technology. He also interviews the world’s greatest founders, operators, investors, and innovators.